6 recruiting, 1 completed, 1 not yet recruiting, 1 unknown. 6 Phase 2, 3 Phase 1, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 3, Completed 1, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 3 | Recruiting 2, Unknown 1 |
| Phase 3 | 1 | Recruiting 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Metastatic Biliary Tract Carcinoma: new trials by email Literature Review of Metastatic Biliary Tract Carcinoma trials Research Report on Metastatic Biliary Tract Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 29 | 2026-11-01 | 2026-09-10 |
| BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion Biospecimen Collection, Computed Tomography, Pemetrexed - Metastatic Biliary Tract Carcinoma, Metastatic Colon Carcinoma | Phase 1 / Phase 2 | Recruiting | Northwestern University | 72 | 2026-08-21 | 2026-08-25 |
| Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers Zolbetuximab, mFOLFOX6, CAPOX - Advanced Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma | Phase 2 | Not yet recruiting | Midhun Malla | 32 | 2026-08-01 | 2026-07-24 |
| Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study Biospecimen Collection, Immune Checkpoint Inhibitor - Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 160 | 2026-04-24 | 2026-10-13 |
| Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer Emavusertib, Gemcitabine, Cisplatin - Metastatic Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma | Phase 1 | Recruiting | Washington University School of Medicine | 48 | 2026-03-27 | 2026-04-03 |
| Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients Trastuzumab, Chemotherapy - Biliary Tract Cancer, HER2-positive Cancer | Phase 3 | Recruiting | Tata Memorial Centre | 220 | 2023-07-21 | 2025-07-14 |
| CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Biospecimen Collection, Computed Tomography, Devimistat - Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma | Phase 2 | Recruiting | Northwestern University | 94 | 2023-03-08 | 2023-03-10 |
| Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer Fluorouracil, Irinotecan Sucrosofate, Laboratory Biomarker Analysis - Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Unknown | Academic and Community Cancer Research United | 18 | 2018-11-02 | 2024-05-17 |
| A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy Regorafenib - Metastatic Biliary Tract Carcinoma | Phase 2 | Completed | Nathan Bahary, MD | 43 | 2014-01-01 | 2019-01-30 |
Biliary Tract Neoplasms (3) · Cholangiocarcinoma (2) · Colorectal Neoplasms (2) · Gallbladder Neoplasms (2) · Gastrointestinal Neoplasms (2) · Lung Neoplasms (2) · Neoplasm Metastasis (2) · Pancreatic Neoplasms (2) · Adenocarcinoma of Lung (1) · Bile Duct Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Colonic Neoplasms (1)
Digestive System Diseases (8) · Digestive System Neoplasms (8) · Neoplasms (8) · Neoplasms by Site (8) · Adenocarcinoma (4) · Biliary Tract Diseases (4) · Carcinoma (4) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4) · Colonic Diseases (3) · Gastrointestinal Diseases (3) · Intestinal Diseases (3) · Intestinal Neoplasms (3) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2)
Gemcitabine (4) · Specimen Handling (4) · Cisplatin (3) · Fluorouracil (2) · Magnetic Resonance Spectroscopy (2) · dehydroftorafur (2) · durvalumab (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 130-nm albumin-bound paclitaxel (1) · CA-4948 (1) · Disulfides (1) · Drug Therapy (1) · Hydroxychloroquine (1) · Immune Checkpoint Inhibitors (1) · Immunoglobulin G (1)
Northwestern University (2) · Academic and Community Cancer Research United (1) · Midhun Malla (1) · Nathan Bahary, MD (1) · OHSU Knight Cancer Institute (1) · Ohio State University Comprehensive Cancer Center (1) · Tata Memorial Centre (1) · Washington University School of Medicine (1)
United States (8) · India (1)
Devalingam Mahalingam (1) · Devalingam Mahalingam, MD, PhD (1) · Midhun Malla, MD, MS (1) · Nathan Bahary, MD, PhD (1) · Olivia Aranha, M.D., Ph.D. (1) · Rajat Thawani (1) · Sameek Roychowdhury, MD, PhD (1) · Tanios S Bekaii-Saab (1) · Vaibhav Sahai, MBBS, MS (1) · Vikas Ostwal, DM (1)
P30CA060553 (2), P30CA015083 (1)